FY2025 EPS Estimates for AC Immune Lifted by HC Wainwright

AC Immune (NASDAQ:ACIU) – Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for AC Immune in a report issued on Wednesday, November 5th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.85) for the year, up from their prior forecast of ($0.87). The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune’s FY2026 earnings at ($0.88) EPS, FY2027 earnings at $0.13 EPS, FY2028 earnings at $1.30 EPS and FY2029 earnings at $1.90 EPS.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, October 8th. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of AC Immune in a research report on Tuesday. Finally, Zacks Research raised AC Immune from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.00.

AC Immune Stock Up 0.6%

NASDAQ:ACIU opened at $3.45 on Friday. AC Immune has a 12-month low of $1.43 and a 12-month high of $4.00. The firm has a market capitalization of $346.41 million, a PE ratio of -5.95 and a beta of 1.58. The firm has a 50-day moving average price of $2.91 and a 200 day moving average price of $2.28.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Tuesday, November 4th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.The firm had revenue of $0.95 million during the quarter, compared to analysts’ expectations of $0.81 million.

Hedge Funds Weigh In On AC Immune

Institutional investors have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise acquired a new stake in AC Immune in the 1st quarter valued at about $50,000. Sei Investments Co. acquired a new stake in AC Immune during the 2nd quarter worth approximately $51,000. Assenagon Asset Management S.A. bought a new stake in AC Immune in the 3rd quarter valued at $549,000. Acadian Asset Management LLC boosted its stake in AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after purchasing an additional 172,796 shares during the period. Finally, BVF Inc. IL grew its holdings in AC Immune by 1.5% in the 1st quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock valued at $37,068,000 after buying an additional 300,000 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.